Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging



Status:Recruiting
Conditions:Arthritis, Rheumatoid Arthritis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:21 - Any
Updated:12/10/2016
Start Date:July 2016
End Date:December 2016
Contact:Bonnie C. Abbruzzese, MS, RD
Email:babbruzzese@navidea.com
Phone:614-822-2327

Use our guide to learn which trials are right for you!

Evaluation of Subcutaneous (SC) Injected Tc 99m Tilmanocept Localization in Active Rheumatoid Arthritis (RA) Subjects by SPECT and SPECT/CT Imaging

Determine the localization of Tc 99m tilmanocept by SPECT and SPECT/CT imaging in subjects
with active RA and concordance with clinical symptomology.


Inclusion Criteria:

- The subject has provided written informed consent with HIPPA authorization before the
initiation of any study-related procedures.

CONTROLS:

- The subject is between 21-45 years of age at the time of consent.

- The subject has not experienced joint pain for at least 4 weeks prior to the consent
date and is deemed to be clinically free of any inflammatory disease(s).

ACTIVE RHEUMATOID ARTHRITIS

- The subject is at least 21 years of age at the time of consent.

- The subject has moderate to severe RA, based on either the 1987American College of
Rheumatology (ACR) score of ≥ 4/7 or the 2010 ACR/EULAR score of ≥ 6/10.

- The subject has a DAS28 of >4.4 (using the ESR).

- If the subject is on methotrexate, they have been at a stable dose for > 4 weeks
prior to the screening visit.

- If the subject is on biologic therapy, they have been at a stable dose > 8 weeks
prior to the screening visit.

- If the subject is on NASIDS or oral corticosteroids, it is ≤ 10mgmg/day or
equivalent, and has been at a stable dose for > 4 weeks prior to the screening visit.

Exclusion Criteria:

- The subject is pregnant or lactating.

- BMI >32.0.

- The subject has had or is currently receiving chemotherapy for a non-inflammatory
related condition or radiation therapy.

Chronic or persistent infection or has any condition that would, in the opinion of the
examining physician, preclude their participation.

- The subject has a known allergy to or has had a reaction to dextran exposure.

- The subject has received an investigational product within 30 days prior to he Tc99m
tilmanocept administration.

- The subject has received any radiopharmaceutical within 7 radioactive half-lives of
that radiopharmaceutical prior to the administration of Tc 99m tilmanocept.
We found this trial at
2
sites
San Francisco, California 94143
Principal Investigator: Jonathan Graf, MD
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Los Angeles, California 90036
Principal Investigator: Lydie Hazan
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials